• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

头孢哌酮:对其体外抗菌活性、药理特性及治疗效果的综述。

Cefoperazone: A review of its in vitro antimicrobial activity, pharmacological properties and therapeutic efficacy.

作者信息

Brogden R N, Carmine A, Heel R C, Morley P A, Speight T M, Avery G S

出版信息

Drugs. 1981 Dec;22(6):423-60. doi: 10.2165/00003495-198122060-00002.

DOI:10.2165/00003495-198122060-00002
PMID:6459224
Abstract

Cefoperazone is a new 'third generation' semisynthetic injectable cephalosporin. It has a broad spectrum of antibacterial activity which includes Pseudomonas aeruginosa (unlike older cephalosporins), along with the Enterobacteriaceae and other Gram-negative bacteria, Gram-positive bacteria and anaerobic bacteria. Unlike other cephalosporins, cefoperazone is excreted to a considerable extent by extrarenal mechanisms. Given by intravenous or intramuscular injection, cefoperazone is effective against a wide variety of infections caused by Gram-negative or Gram-positive aerobes, including infections of the biliary tract, and in many anaerobic infections. It is generally well tolerated, diarrhoea and skin rashes being the most frequently reported side effects.

摘要

头孢哌酮是一种新型的“第三代”半合成注射用头孢菌素。它具有广谱抗菌活性,包括铜绿假单胞菌(与 older cephalosporins 不同),以及肠杆菌科细菌和其他革兰氏阴性菌、革兰氏阳性菌和厌氧菌。与其他头孢菌素不同,头孢哌酮在很大程度上通过肾外机制排泄。通过静脉或肌肉注射给药,头孢哌酮对由革兰氏阴性或革兰氏阳性需氧菌引起的多种感染有效,包括胆道感染以及许多厌氧菌感染。它通常耐受性良好,腹泻和皮疹是最常报告的副作用。

相似文献

1
Cefoperazone: A review of its in vitro antimicrobial activity, pharmacological properties and therapeutic efficacy.头孢哌酮:对其体外抗菌活性、药理特性及治疗效果的综述。
Drugs. 1981 Dec;22(6):423-60. doi: 10.2165/00003495-198122060-00002.
2
Antimicrobial activity, pharmacokinetics, adverse reactions, and therapeutic indications of cefoperazone.头孢哌酮的抗菌活性、药代动力学、不良反应及治疗指征
Pharmacotherapy. 1982 Jul-Aug;2(4):185-96. doi: 10.1002/j.1875-9114.1982.tb03186.x.
3
Cefoperazone (Cefobid, Pfizer).头孢哌酮(头孢必,辉瑞公司)。
Drug Intell Clin Pharm. 1983 Jan;17(1):7-11. doi: 10.1177/106002808301700102.
4
Cefoxitin: a review of its antibacterial activity, pharmacological properties and therapeutic use.头孢西丁:抗菌活性、药理特性及治疗用途综述
Drugs. 1979 Jan;17(1):1-37. doi: 10.2165/00003495-197917010-00001.
5
Cefuroxime: a review of its antibacterial activity, pharmacological properties and therapeutic use.头孢呋辛:抗菌活性、药理特性及治疗用途综述
Drugs. 1979 Apr;17(4):233-66. doi: 10.2165/00003495-197917040-00001.
6
Clinical and laboratory evaluation of cefoperazone.
Clin Ther. 1981;4(3):164-74.
7
In vitro combination effects of cefsulodin, moxalactam and cefoperazone with four aminoglycosides on nonfermenting nosocomial gram-negative bacteria.
Arzneimittelforschung. 1982;32(5):531-3.
8
Ceftizoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.头孢唑肟:抗菌活性、药代动力学特性及治疗用途综述
Drugs. 1985 Apr;29(4):281-329. doi: 10.2165/00003495-198529040-00001.
9
Third-generation cephalosporins: a critical evaluation.第三代头孢菌素:批判性评价
Clin Pharm. 1984 Jul-Aug;3(4):351-73.
10
Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.头孢曲松。对其抗菌活性、药理特性及治疗用途的综述。
Drugs. 1984 Jun;27(6):469-527. doi: 10.2165/00003495-198427060-00001.

引用本文的文献

1
Efficacy of cefoperazone-sulbactam as a component of combination therapy for carbapenem-resistant Acinetobacter baumannii bloodstream infection in intensive care units: a multicenter retrospective propensity score-matched study.头孢哌酮-舒巴坦作为重症监护病房耐碳青霉烯鲍曼不动杆菌血流感染联合治疗方案组成部分的疗效:一项多中心回顾性倾向评分匹配研究
BMC Infect Dis. 2025 Jul 1;25(1):872. doi: 10.1186/s12879-025-11205-w.
2
Assessing the therapeutic efficacy of Cefoperazone Sodium and Sulbactam Sodium in managing surgical site infections: a retrospective analysis.评估头孢哌酮钠舒巴坦钠治疗手术部位感染的疗效:回顾性分析。
Sci Rep. 2024 Nov 8;14(1):27164. doi: 10.1038/s41598-024-77906-5.
3

本文引用的文献

1
Comparison of in vitro activities of eight beta-lactamase-stable cephalosporins against beta-lactamase-producing gram-negative bacilli.八种β-内酰胺酶稳定型头孢菌素对产β-内酰胺酶革兰氏阴性杆菌的体外活性比较
Antimicrob Agents Chemother. 1981 Mar;19(3):407-13. doi: 10.1128/AAC.19.3.407.
2
Activity of beta-lactamase produced by Bacteroides fragilis against newly introduced cephalosporins.脆弱拟杆菌产生的β-内酰胺酶对新引入头孢菌素的活性。
Antimicrob Agents Chemother. 1980 Apr;17(4):736-7. doi: 10.1128/AAC.17.4.736.
3
Antibacterial activity of ceftizoxime, a beta-lactamase-stable cephalosporin.
Multicenter study on clinical outcomes and poor prognostic factors in patients with Klebsiella pneumoniae bacteremia receiving cefoperazone/sulbactam treatment.
多中心研究:头孢哌酮/舒巴坦治疗肺炎克雷伯菌血症患者的临床结局和不良预后因素。
Eur J Clin Microbiol Infect Dis. 2024 Sep;43(9):1777-1785. doi: 10.1007/s10096-024-04892-x. Epub 2024 Jul 12.
4
Novel Siderophore Cephalosporin and Combinations of Cephalosporins with β-Lactamase Inhibitors as an Advancement in Treatment of Ventilator-Associated Pneumonia.新型铁载体头孢菌素及头孢菌素与β-内酰胺酶抑制剂的联合用药作为呼吸机相关性肺炎治疗的进展
Antibiotics (Basel). 2024 May 14;13(5):445. doi: 10.3390/antibiotics13050445.
5
Combined PK/PD Index May Be a More Appropriate PK/PD Index for Cefoperazone/Sulbactam against in Patients with Hospital-Acquired Pneumonia.对于医院获得性肺炎患者,联合药代动力学/药效学指数可能是头孢哌酮/舒巴坦更合适的药代动力学/药效学指数。
Antibiotics (Basel). 2022 May 23;11(5):703. doi: 10.3390/antibiotics11050703.
6
Non-responder phenotype reveals apparent microbiome-wide antibiotic tolerance in the murine gut.无应答表型揭示了鼠肠道中明显的微生物组范围的抗生素耐药性。
Commun Biol. 2021 Mar 9;4(1):316. doi: 10.1038/s42003-021-01841-8.
7
Discovery of COVID-19 Inhibitors Targeting the SARS-CoV-2 Nsp13 Helicase.靶向严重急性呼吸综合征冠状病毒2(SARS-CoV-2)非结构蛋白13(Nsp13)解旋酶的新型冠状病毒肺炎(COVID-19)抑制剂的发现
J Phys Chem Lett. 2020 Nov 5;11(21):9144-9151. doi: 10.1021/acs.jpclett.0c02421. Epub 2020 Oct 14.
8
Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase.靶向严重急性呼吸综合征冠状病毒2(SARS-CoV-2)非结构蛋白13(Nsp13)解旋酶的新型冠状病毒肺炎(COVID-19)抑制剂的发现
bioRxiv. 2020 Aug 10:2020.08.09.243246. doi: 10.1101/2020.08.09.243246.
9
Pharmacokinetics of cephalosporins in the neonate: a review.头孢菌素类药物在新生儿中的药代动力学:综述。
Clinics (Sao Paulo). 2011;66(7):1267-74. doi: 10.1590/s1807-59322011000700024.
10
Susceptibility of anaerobic bacteria from several French hospitals to three major antibiotics.来自法国几家医院的厌氧菌对三种主要抗生素的敏感性
Antimicrob Agents Chemother. 1984 Jun;25(6):764-6. doi: 10.1128/AAC.25.6.764.
头孢唑肟(一种对β-内酰胺酶稳定的头孢菌素)的抗菌活性
Antimicrob Agents Chemother. 1980 Apr;17(4):583-90. doi: 10.1128/AAC.17.4.583.
4
Pharmacokinetics, protein binding, and predicted extravascular distribution of moxalactam in normal and renal failure subjects.正常受试者和肾衰竭受试者中莫西拉坦的药代动力学、蛋白结合及预计的血管外分布
Antimicrob Agents Chemother. 1981 Sep;20(3):378-81. doi: 10.1128/AAC.20.3.378.
5
[Clinical studies on cefoperazone treatment for bile duct infections (author's transl)].头孢哌酮治疗胆管感染的临床研究(作者译)
Jpn J Antibiot. 1981 Jun;34(6):934-8.
6
Cefoperazone in lower respiratory tract infections.头孢哌酮治疗下呼吸道感染
Drugs. 1981;22 Suppl 1:96-9. doi: 10.2165/00003495-198100221-00020.
7
Clinical studies with cefoperazone in the treatment of bacterial infections in surgical practice.头孢哌酮治疗外科手术中细菌感染的临床研究。
Drugs. 1981;22 Suppl 1:87-93. doi: 10.2165/00003495-198100221-00018.
8
Cefoperazone in the treatment of severe or complicated infections.
Drugs. 1981;22 Suppl 1:76-86. doi: 10.2165/00003495-198100221-00017.
9
A clinical trial with cefoperazone in pneumonia and pyelonephritis.一项使用头孢哌酮治疗肺炎和肾盂肾炎的临床试验。
Drugs. 1981;22 Suppl 1:72-5. doi: 10.2165/00003495-198100221-00016.
10
Cefoperazone in Klebsiella meningitis: a case report.
Drugs. 1981;22 Suppl 1:69-71. doi: 10.2165/00003495-198100221-00015.